BrainsWay
Market Cap
₪472.6m
Last Updated
2021/05/15 16:18 UTC
Data Sources
Company Financials +
Executive Summary
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has BrainsWay's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BWAY is more volatile than 75% of IL stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BWAY's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of IL stocks.
Market Performance
7 Day Return
4.3%
BWAY
-0.3%
IL Medical Equipment
-0.8%
IL Market
1 Year Return
3.1%
BWAY
68.0%
IL Medical Equipment
42.2%
IL Market
Return vs Industry: BWAY underperformed the IL Medical Equipment industry which returned 68% over the past year.
Return vs Market: BWAY underperformed the IL Market which returned 42.2% over the past year.
Shareholder returns
| BWAY | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.3% | -0.3% | -0.8% |
| 30 Day | -5.3% | 1.4% | 3.2% |
| 90 Day | -1.2% | 1.7% | 8.5% |
| 1 Year | 3.1%3.1% | 68.8%68.0% | 45.5%42.2% |
| 3 Year | -14.1%-14.1% | 129.7%127.4% | 45.4%34.4% |
| 5 Year | -12.9%-12.9% | 95.3%91.3% | 89.9%62.5% |
Long-Term Price Volatility Vs. Market
How volatile is BrainsWay's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Would Shareholders Who Purchased BrainsWay's (TLV:BWAY) Stock Five Years Be Happy With The Share price Today?2 months ago | Simply Wall St
What Is The Ownership Structure Like For Brainsway Ltd. (TLV:BWAY)?Valuation
Is BrainsWay undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BWAY (₪14.26) is trading below our estimate of fair value (₪52.78)
Significantly Below Fair Value: BWAY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BWAY is unprofitable, so we can't compare its PE Ratio to the IL Medical Equipment industry average.
PE vs Market: BWAY is unprofitable, so we can't compare its PE Ratio to the IL market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BWAY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BWAY is overvalued based on its PB Ratio (4.9x) compared to the IL Medical Equipment industry average (2.2x).
Future Growth
How is BrainsWay forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
55.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BWAY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BWAY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BWAY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BWAY's revenue (20.3% per year) is forecast to grow faster than the IL market (7.5% per year).
High Growth Revenue: BWAY's revenue (20.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BWAY's Return on Equity is forecast to be high in 3 years time
Past Performance
How has BrainsWay performed over the past 5 years?
-22.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BWAY is currently unprofitable.
Growing Profit Margin: BWAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BWAY is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare BWAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BWAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.7%).
Return on Equity
High ROE: BWAY has a negative Return on Equity (-27.43%), as it is currently unprofitable.
Financial Health
How is BrainsWay's financial position?
Financial Position Analysis
Short Term Liabilities: BWAY's short term assets ($24.3M) exceed its short term liabilities ($6.8M).
Long Term Liabilities: BWAY's short term assets ($24.3M) exceed its long term liabilities ($7.6M).
Debt to Equity History and Analysis
Debt Level: BWAY is debt free.
Reducing Debt: BWAY has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BWAY has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BWAY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is BrainsWay current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BWAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BWAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BWAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BWAY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BWAY's dividend in 3 years as they are not forecast to pay a notable one for the IL market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Chris von Jako (51 yo)
1.33yrs
Tenure
Dr. Christopher R. von Jako, Ph.D., also know as chris, Serves as President and Chief Executive Officer of Brainsway Ltd. Since January 2020. He serves as an Independent Director of NinePoint Medical, Inc....
Leadership Team
Experienced Management: BWAY's management team is considered experienced (4.6 years average tenure).
Board Members
Experienced Board: BWAY's board of directors are considered experienced (3.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49%.
Top Shareholders
Company Information
BrainsWay Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: BrainsWay Ltd.
- Ticker: BWAY
- Exchange: TASE
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: ₪472.611m
- Shares outstanding: 33.14m
- Website: https://www.brainsway.com
Number of Employees
Location
- BrainsWay Ltd.
- Bynet Building
- 3rd Floor
- Jerusalem
- 9777518
- Israel
Listings
Biography
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic s...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/15 16:18 |
| End of Day Share Price | 2021/05/13 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.